HK1095841A1 - M-csf-specific monoclonal antibody and uses thereof m-csf- - Google Patents

M-csf-specific monoclonal antibody and uses thereof m-csf-

Info

Publication number
HK1095841A1
HK1095841A1 HK07103227.2A HK07103227A HK1095841A1 HK 1095841 A1 HK1095841 A1 HK 1095841A1 HK 07103227 A HK07103227 A HK 07103227A HK 1095841 A1 HK1095841 A1 HK 1095841A1
Authority
HK
Hong Kong
Prior art keywords
csf
monoclonal antibody
specific monoclonal
specific
antibody
Prior art date
Application number
HK07103227.2A
Other languages
English (en)
Chinese (zh)
Inventor
Cheng Liu
Deborah Lee Zimmerman
Gregory Martin Harrowe
Kirston Koths
William Michael Kavanaugh
Li Long
Maria Calderon-Cacia
Arnold H Horwitz
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of HK1095841A1 publication Critical patent/HK1095841A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK07103227.2A 2004-01-07 2007-03-26 M-csf-specific monoclonal antibody and uses thereof m-csf- HK1095841A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53518104P 2004-01-07 2004-01-07
US57641704P 2004-06-02 2004-06-02
PCT/US2005/000546 WO2005068503A2 (en) 2004-01-07 2005-01-06 M-csf-specific monoclonal antibody and uses thereof

Publications (1)

Publication Number Publication Date
HK1095841A1 true HK1095841A1 (en) 2007-05-18

Family

ID=34798846

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07103227.2A HK1095841A1 (en) 2004-01-07 2007-03-26 M-csf-specific monoclonal antibody and uses thereof m-csf-

Country Status (25)

Country Link
US (6) US20090324604A1 (de)
EP (3) EP1704166B1 (de)
JP (3) JP5422101B2 (de)
KR (2) KR101307868B1 (de)
CN (2) CN107090034B (de)
AU (1) AU2005205533B2 (de)
BR (1) BRPI0506726B8 (de)
CA (1) CA2552750C (de)
CY (1) CY1121162T1 (de)
DK (2) DK2311873T3 (de)
EC (1) ECSP066756A (de)
ES (2) ES2689328T3 (de)
HK (1) HK1095841A1 (de)
HU (2) HUE026132T2 (de)
IL (1) IL176755A (de)
LT (1) LT2311873T (de)
MX (1) MXPA06007856A (de)
NO (1) NO341391B1 (de)
NZ (1) NZ548785A (de)
PL (2) PL1704166T3 (de)
PT (2) PT2311873T (de)
RU (2) RU2401277C2 (de)
SI (2) SI1704166T1 (de)
TR (1) TR201815885T4 (de)
WO (1) WO2005068503A2 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913697B2 (en) 2001-02-14 2005-07-05 Science & Technology Corporation @ Unm Nanostructured separation and analysis devices for biological membranes
JP2006501449A (ja) 2002-09-27 2006-01-12 ザ ジェネラル ホスピタル コーポレーション 細胞分離のためのマイクロ流体デバイスおよびその使用
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
KR101307868B1 (ko) 2004-01-07 2013-09-12 조마 테크놀로지 리미티드 Ｍ-ｃｓｆ-특이적 단일클론 항체 및 그것의 사용
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
EP1913027B1 (de) * 2005-07-28 2015-03-04 Novartis AG M-csf-spezifische monoklonale antikörper und anwendungen davon
EP1913028B1 (de) * 2005-07-28 2015-03-04 Novartis AG Anwendung von antikörpern gegen m-csf
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20090246208A1 (en) * 2006-01-05 2009-10-01 Novartis Ag Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
ES2918323T3 (es) 2006-05-31 2022-07-15 Childrens Medical Center Células madre mesenquimatosas ABC5 positivas como inmunomoduladores
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
KR101368596B1 (ko) * 2006-08-18 2014-03-17 조마 테크놀로지 리미티드 Ｐｒｌｒ 특이적 항체 및 그 용도
AU2007292890A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
CA2665528C (en) * 2006-10-12 2018-01-23 The University Of Tokyo Diagnosis and treatment of cancer using anti-ereg antibody
WO2008084106A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
JP5889527B2 (ja) 2007-04-12 2016-03-22 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌療法のためのａｂｃｂ５標的化
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
US8604170B2 (en) 2008-03-14 2013-12-10 Transgene S.A. Antibody against the CSF-1R
EP2116556B1 (de) * 2008-05-09 2016-03-23 AbbVie Deutschland GmbH & Co KG Antikörper zu Rezeptor für Endprodukte der fortgeschrittenen Glykierung (RAGE) und Verwendungen davon
EP2436397B1 (de) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmazeutische zusammensetzung mit einem antagonisten eines liganden der egf-familie als bestandteil
AU2011217848B8 (en) 2010-02-18 2015-09-24 The Regents Of The University Of California Integrin aVB8 neutralizing antibody
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
WO2012096917A1 (en) * 2011-01-10 2012-07-19 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof
GB2502462B (en) 2011-01-10 2018-08-08 Univ Michigan Regents Stem cell factor inhibitor
CA2828289C (en) * 2011-03-29 2020-07-21 Roche Glycart Ag Antibody fc variants
US9243066B2 (en) * 2011-07-18 2016-01-26 University Of Melbourne Use of M-CSF antibodies in the treatment of osteoarthritis or pain
US9492569B2 (en) 2011-08-17 2016-11-15 The Regents Of The University Of California Antibodies that bind integrin alpha-V beta-8
IL296507A (en) * 2011-10-10 2022-11-01 Hope City Meditops and Meditop binding antibodies and their use
RU2473367C1 (ru) * 2011-11-22 2013-01-27 Федеральное государственное унитарное предприятие "Научно-производственное объединение "Радиевый институт им. В.Г. Хлопина" Способ изготовления стента для радиационной терапии злокачественных опухолей желчного протока
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
CN104540519B (zh) 2012-05-21 2018-06-01 基因泰克公司 抗Ly6E抗体和免疫缀合物及使用方法
RS57704B1 (sr) 2012-07-13 2018-12-31 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova primena u lečenju vaskularnih bolesti oka
DK2900263T3 (da) 2012-09-26 2019-07-29 Univ Wuerzburg J Maximilians Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15)
JP6739329B2 (ja) 2013-03-14 2020-08-12 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖコア脂質結合ドメインモノクローナル抗体
WO2014143342A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
BR112015023239A8 (pt) 2013-03-14 2018-04-17 Abbott Lab ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
SG11201507871XA (en) 2013-04-12 2015-10-29 Morphosys Ag Antibodies targeting m-csf
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
EP3043820A4 (de) 2013-09-13 2017-07-12 F. Hoffmann-La Roche AG Verfahren und zusammensetzungen mit gereinigten rekombinanten polypeptiden
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
KR20160068963A (ko) 2013-10-21 2016-06-15 제넨테크, 인크. 항-Ly6E 항체 및 사용 방법
JP6685225B2 (ja) * 2013-12-16 2020-04-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 形質細胞様樹状細胞の枯渇
AU2015238264B2 (en) 2014-03-26 2020-09-03 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
TW201632202A (zh) 2015-01-30 2016-09-16 諾華公司 乳癌之治療
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
AU2016239951A1 (en) * 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Polypeptides
CA2989586A1 (en) 2015-06-16 2016-12-22 Pfizer, Inc. Pd-l1 antagonist combination treatments
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
MX2018001263A (es) * 2015-07-29 2018-04-13 Novartis Ag Nueva combinacion para el uso en el tratamiento del cancer.
MA42843A (fr) 2015-09-16 2018-07-25 Ablexis Llc Anticorps anti-cd115
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US11034761B2 (en) 2016-07-29 2021-06-15 Icahn School Of Medicine At Mount Sinai Compositions and methods for reducing adiposity by inhibiting FSH/FSHR
CA3039451A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
WO2018089300A1 (en) * 2016-11-10 2018-05-17 Merck Sharp & Dohme Corp. Ilt3 ligand
US10736976B2 (en) 2016-12-01 2020-08-11 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
EP3592373A4 (de) * 2017-03-09 2021-01-20 Shriners Hospitals for Children Kollagenassays vom typ x und verfahren zu ihrer verwendung
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3618871A4 (de) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. Formulierungen von anti-lag3-antikörpern und co-formulierungen von anti-lag3-antikörpern und anti-pd-1-antikörpern
JP6356317B1 (ja) * 2017-06-05 2018-07-11 国立大学法人北海道大学 多発性骨髄腫患者の医薬への応答性を判定する方法、並びに多発性骨髄腫患者における骨病変の予防及び／又は治療のための医薬
US11312783B2 (en) 2017-06-22 2022-04-26 Novartis Ag Antibody molecules to CD73 and uses thereof
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
US11976121B2 (en) 2017-07-20 2024-05-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. CD123-binding chimeric antigen receptors
CA3081602A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
BR112020015052A2 (pt) * 2018-02-09 2020-12-08 Genmab A/S Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
MX2021004356A (es) * 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
US20240245670A1 (en) 2018-12-20 2024-07-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
EP3924054A1 (de) 2019-02-15 2021-12-22 Novartis AG 3-(1-oxo-5- (piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dionderivate und ihre verwendungen
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US20220389117A1 (en) * 2019-10-17 2022-12-08 National Health Research Institutes Use of succinate as biomarker in diagnosis and treatment of cancers
WO2021123902A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
CN111087470B (zh) * 2020-01-19 2022-05-10 中国人民解放军第四军医大学 一种抗人CD47单克隆抗体7G4mAb及其应用
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
TW202409288A (zh) * 2022-07-25 2024-03-01 美商英特瑞斯生物療法公司 突變多肽、包含該等突變多肽之組合物及其用途

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
GB2056642B (en) 1979-08-08 1983-05-11 Dawson Int Radio frequency drying of textile material
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
JPS6213552A (ja) 1985-07-12 1987-01-22 Nippon Light Metal Co Ltd 流電陽極用アルミニウム合金
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4929700A (en) 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
ATE106249T1 (de) 1987-11-05 1994-06-15 Hybritech Inc Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ATE141290T1 (de) 1989-02-10 1996-08-15 Cetus Oncology Corp M-csf-monoklonale antikörper, die ein neutralisierendes konformationales epitop erkennen
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (de) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformationsvektoren für Hefe Yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB8915572D0 (en) 1989-07-07 1989-08-23 Natural Environment Res Use of bluetongue virus proteins as vaccine components
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH05503098A (ja) 1989-12-15 1993-05-27 カイロン　コーポレイション セプシスの処理のためのサイトカイン抗体
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE356869T1 (de) * 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH0517367A (ja) 1991-07-08 1993-01-26 Green Cross Corp:The 骨粗鬆症治療剤
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH0595794A (ja) * 1991-10-04 1993-04-20 Otsuka Pharmaceut Co Ltd ヒトｍ−ｃｓｆ抗体及びヒトｍ−ｃｓｆの測定法
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
EP0626012B1 (de) 1992-02-11 2003-07-09 Cell Genesys, Inc. Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
JPH06319584A (ja) * 1993-05-07 1994-11-22 Morinaga Milk Ind Co Ltd 抗ｍ−ｃｓｆモノクロ−ナル抗体と、この抗体を産生 するハイブリド−マ
US5807549A (en) 1993-05-21 1998-09-15 Research Corporation Technologies, Inc. Lymphocyte chemoattractant factor and uses thereof
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US6054287A (en) 1994-05-27 2000-04-25 Methodist Hospital Of Indiana, Inc. Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species
DK0784684T3 (da) * 1994-09-16 2007-12-17 Cancer Res Inst Of Contra Cost Rekombinante peptider afledt af Mc3 anti BA46 antistoffet, fremgangsmåder til anvendelse deraf og fremgangsmåder til humanisering af antistofpeptider
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP1709970A1 (de) 1995-04-27 2006-10-11 Abgenix, Inc. Menschliche Antikörper gegen EGFR, von immunisierten transgenen Mäusen produziert
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6025146A (en) * 1995-06-05 2000-02-15 Chiron Corporation Identification of M-CSF agonists and antagonists
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
EP2305027B1 (de) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgene Saügertiere, die menschlichen Ig-loci einschließlich mehrere VH und Vkappa Regionen enthalten, und davon erhaltene Antikörper
US6017757A (en) 1997-02-20 2000-01-25 Mississippi State University Isolated viable nematode intestinal cells
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
AU734758B2 (en) 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
HU229841B1 (en) 1997-04-15 2014-09-29 Daiichi Sankyo Co Ltd Antibodies against obm
US20030044772A1 (en) 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
WO1999029345A1 (en) 1997-12-05 1999-06-17 La Jolla Institute For Experimental Medicine Inhibition of tumor growth by macrophage intervention
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2197885T3 (es) * 1999-10-28 2004-01-16 Hofbauer, Reinhold Uso de inhibidores csf-1.
WO2001034177A2 (en) * 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
JP4503155B2 (ja) 2000-08-28 2010-07-14 北川工業株式会社 導電スペーサ
GB0028647D0 (en) 2000-11-24 2001-01-10 Nextgen Sciences Ltd Apparatus for chemical assays
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
WO2003059395A2 (fr) 2002-01-03 2003-07-24 Transgene Antisens diriges contre le csf-1 humain
US20030138857A1 (en) 2002-01-15 2003-07-24 Goldschmidt-Clermont Pascal J. Method of inhibiting atherosclerotic plaque destabilization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DK1527100T3 (da) 2002-03-29 2009-09-07 Schering Corp Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
JPWO2003093238A1 (ja) 2002-05-01 2005-09-08 麒麟麦酒株式会社 マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体
WO2004002424A2 (en) * 2002-06-28 2004-01-08 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
JP4727992B2 (ja) * 2002-11-15 2011-07-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌転移および癌転移に伴なう骨量減少を予防および処置するための方法
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
KR101307868B1 (ko) 2004-01-07 2013-09-12 조마 테크놀로지 리미티드 Ｍ-ｃｓｆ-특이적 단일클론 항체 및 그것의 사용
EP1913027B1 (de) * 2005-07-28 2015-03-04 Novartis AG M-csf-spezifische monoklonale antikörper und anwendungen davon
JP5095794B2 (ja) 2010-10-05 2012-12-12 ヤフー株式会社 レコメンデーション連携装置及びその方法
JP6319584B2 (ja) 2015-02-27 2018-05-09 京セラドキュメントソリューションズ株式会社 画像形成システム

Also Published As

Publication number Publication date
LT2311873T (lt) 2018-10-25
KR101352853B1 (ko) 2014-02-04
RU2006128586A (ru) 2008-02-20
EP2311873B1 (de) 2018-08-29
NO20063569L (no) 2006-10-06
JP5422101B2 (ja) 2014-02-19
ES2543833T3 (es) 2015-08-24
EP3476861A1 (de) 2019-05-01
CY1121162T1 (el) 2020-05-29
SI1704166T1 (sl) 2015-06-30
US20170152311A1 (en) 2017-06-01
KR20120107147A (ko) 2012-09-28
PT1704166E (pt) 2015-09-04
BRPI0506726A (pt) 2007-05-02
US11034759B2 (en) 2021-06-15
DK2311873T3 (en) 2018-11-26
BRPI0506726B1 (pt) 2021-05-11
AU2005205533B2 (en) 2012-03-22
BRPI0506726B8 (pt) 2021-05-25
ECSP066756A (es) 2006-12-29
EP1704166A2 (de) 2006-09-27
AU2005205533A1 (en) 2005-07-28
CN101189264A (zh) 2008-05-28
NO341391B1 (no) 2017-10-30
CN107090034A (zh) 2017-08-25
US20090324604A1 (en) 2009-12-31
US9079956B2 (en) 2015-07-14
TR201815885T4 (tr) 2018-11-21
DK1704166T3 (en) 2015-06-01
NZ548785A (en) 2011-08-26
IL176755A0 (en) 2006-10-31
JP2008500806A (ja) 2008-01-17
PT2311873T (pt) 2018-11-20
CN101189264B (zh) 2017-10-10
EP1704166B1 (de) 2015-04-29
RU2401277C2 (ru) 2010-10-10
US9522186B2 (en) 2016-12-20
ES2689328T3 (es) 2018-11-13
HUE026132T2 (en) 2016-05-30
KR101307868B1 (ko) 2013-09-12
US20140242071A1 (en) 2014-08-28
PL1704166T3 (pl) 2015-10-30
JP2011078435A (ja) 2011-04-21
PL2311873T3 (pl) 2019-01-31
HUE039803T2 (hu) 2019-02-28
CN107090034B (zh) 2021-10-01
WO2005068503A2 (en) 2005-07-28
CA2552750C (en) 2021-11-09
WO2005068503A3 (en) 2005-11-10
US20190263900A1 (en) 2019-08-29
SI2311873T1 (sl) 2018-12-31
EP2311873A1 (de) 2011-04-20
JP2013208125A (ja) 2013-10-10
KR20070034455A (ko) 2007-03-28
US20160015809A1 (en) 2016-01-21
RU2010121565A (ru) 2011-12-10
CA2552750A1 (en) 2005-07-28
US9926371B2 (en) 2018-03-27
US20180171009A1 (en) 2018-06-21
MXPA06007856A (es) 2007-03-23
IL176755A (en) 2015-03-31

Similar Documents

Publication Publication Date Title
IL272883A (en) Monoclonal antibodies and their uses
IL176755A0 (en) M-csf-specific monoclonal antibody and uses thereof
IL190502A0 (en) Anti-addl monoclonal antibody and use thereof
EP1717250A4 (de) Monoklonaler antikörper und dessen verwendung
IL187710A0 (en) Anti-trkb monoclonal antibodies and uses thereof
EP1940466A4 (de) Monoklonaler antikörper gegen addl und anwendung davon
ZA200608100B (en) IRTA-5 antibodies and their uses
IL222922A (en) Antibodies against neurophilin-1 and their use
EP1787998A4 (de) Antikörper und deren verwendung
IL184659A0 (en) Antibody variants and uses thereof
IL178356A0 (en) Dr5 antibodies and uses thereof
HK1111177A1 (en) M-csf specific monoclonal antibody and uses thereof m-csf
SG10201404801YA (en) Monoclonal antibody
ZA200900514B (en) Anti-iL-6 monoclonal antibodies and uses thereof
AP2008004471A0 (en) Anti-Alpha2 Intergin antibodies and their uses
IL184024A0 (en) Irta-5 antibodies and their uses
ZA200703406B (en) Anti-ADDL antibodies and uses thereof
EP2077325A4 (de) Monoklonaler antikörper und dessen verwendung
EP2048162A4 (de) Neuer monoklonaler antikörper und seine verwendung
EP1774331A4 (de) Cytoxan-antikörper und immunoassay
ZA200706336B (en) CD20 antibody variants and uses thereof
EP1780221A4 (de) Anti-synoviolin-antikörper
EP1712564A4 (de) Monoklonaler anti-nc1-antikörper
GB0415644D0 (en) Monoclonal antibody
ZA200702281B (en) IRTA-4 antibodies and their uses